Axio BioPharma Inc., a biomanufacturing company leveraging AI for mammalian protein production, and Likarda Inc., an advanced drug delivery and formulation technologies company, entered a strategic partnership to integrate Likarda’s delivery technologies with Axio’s manufacturing capabilities. The alliance aims to create a more efficient and scalable path to clinical manufacturing for clients across the biopharmaceutical sector.
Axio BioPharma will incorporate Likarda’s delivery platforms— including its Core-Shell Spherification (CSS) hydrogel technology for encapsulation, stability, and controlled release —into its service offering to enhance workflows for monoclonal antibodies (mAbs), bispecifics, and Fc-fusions. Likarda will also offer Axio’s discovery-to-GMP manufacturing capabilities to its client base, supporting programs in need of high-quality protein production and scalable manufacturing solutions.
“This partnership brings delivery innovation directly into the development process, helping our clients move faster and make better decisions,” said Justin Byers, CEO of Axio BioPharma. “By aligning earlier on both delivery and manufacturing, we reduce friction, shorten timelines, and provide integrated solutions that truly support our clients’ goals.”
“At Likarda, we believe that delivery should never be an afterthought—it should be part of the development strategy from day one,” said Dr. Stella Vnook, CEO of Likarda Inc. “Partnering with Axio allows us to integrate our encapsulation and formulation technologies earlier in the drug development process, where they can have the greatest impact on stability, efficacy, and patient experience. Importantly, it provides seamless integration to scaled manufacturing for our clients. Together, we’re creating a smarter, more connected path from discovery to clinic.”
